CTRI/2021/08/035993已完成2 期
A Phase 2 randomized, multi-centric, Clinical Trial of Heterologus Prime-Boost Combination of SARSCoV-2 Vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXIN®) with BBV154(Adenoviral Intranasal COVID-19 vaccine) in Healthy Volunteers. - BBV152/BBV154
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 608
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Ability to provide written informed consent.
- •2.Participants of either gender, ages between =18 years - <65 Years.
- •3.Good general health as determined by the discretion of investigator (vital signs (heart rate =60 to =100 bpm; blood pressure systolic =90 mm Hg and <140 mm Hg; diastolic = 60 mm Hg and <90 mm Hg; oral temperature <100.4ºF), medical history, and physical examination).
- •4.Expressed interest and availability to fulfil the study requirements.
- •5.For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination
- •6.Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination
- •7.Participants must refrain from blood/plasma or any other bodily fluid donation from the time of first vaccination until 3 months after the last vaccination
- •8.Agrees not to participate in another clinical trial at any time during the study period.
- •9.Agrees to remain in the study area for the entire duration of the study.
- •10.Willing to allow storage and future use of biological samples for future research
排除标准
- •1.History of any other COVID-19 investigational/or licensed vaccination.
- •2.History of cold, sneezing, nasal obstruction in the past 1 day.
- •3.For women of childbearing potential, a positive urine pregnancy test (within 24 hours of administering each dose of vaccine).
- •4.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days before each dose of vaccine.
- •5.Medical problems because of alcohol or illicit drug use during the past 12 months.
- •6.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period.
- •7.Receipt of any licensed vaccine within four weeks before enrolment in this study.
- •8.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past.
- •9.Receipt of immunoglobulin or other blood products within the three months before vaccination in this study.
- •10.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
- •11.Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed).
- •12.Any history of anaphylaxis concerning vaccination.
- •13.History of any cancer.
- •14.History of severe psychiatric severe conditions likely to affect participation in the study.
- •15.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venipuncture.
- •16.Any other serious chronic illness requiring immediate hospital specialist supervision.
- •17.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
- •Re-Vaccination Exclusion Criteria
- •18.Pregnancy.
- •19.Anaphylactic reaction following administration of the vaccine.
- •20.Virologically confirmed cases of SARS-CoV-2 infection.
研究者
相似试验
招募中
2 期
Treament of multiple myelomaCTRI/2019/09/021385Christian Medical College Vellore
已完成
2 期
A trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapyMalignant neoplasm of prostateCancerProstate cancerISRCTN16465571niversity of Birmingham (UK)15
进行中（未招募）
1 期
CANTATA: Chemotherapy comparison in relapsing Prostate Cancer that has spreadEUCTR2012-003835-40-GBniversity of Birmingham15
已完成
不适用
A multi-centre, phase II - III randomised clinical trial and observational study of defibrotide for the treatment of hepatic veno-occlusive disease after stem cell transplantHepatic veno-occlusive disease (VOD)Digestive SystemOther diseases of liverISRCTN65464501Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
进行中（未招募）
1 期
A randomised phase II/III multi-centre clinical trial of definitive chemo-radiaiton, with or without cetuximab, in carcinoma of the oesophagus - SCOPE 1in-operable carcinoma of the oesophagusMedDRA version: 8.1 Level: LLT Classification code 10030151 Term: Oesophageal cancerEUCTR2006-002241-37-GBVelindre NHS Trust